Jul.26.2022
R & D

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab), for Treatment of Patients with Unresectable or Metastatic Melanoma

 This material is intended to notify the press release issued on July 22 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
 Please click https://www.bms.com/media/press-releases.html for the original press release.